Interferon as a treatment for uveitis associated with multiple sclerosis

British Journal of Ophthalmology

Volumn 89, Issue 10, 2005, Pages 1254-1257

  Becker, Matthias D ^a   Heiligenhaus, A ^b   Hudde, T ^c   Storch Hagenlocher, B ^a   Wildemann, B ^a   Barisani Asenbauer, T ^d   Thimm, C ^e   Stubiger N ^e   Trieschmann, M ^b   Fiehn, C ^a,f  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f Centre of Rheumatic Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER;

ADULT; AQUEOUS HUMOR; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL OBSERVATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYOPATHY; PILOT STUDY; PRIORITY JOURNAL; RESTLESSNESS; RETINA MACULA CYSTOID EDEMA; TREATMENT OUTCOME; TREMOR; UVEITIS; VISUAL ACUITY; VITREOUS BODY; CLINICAL TRIAL; DRUG EFFECT; INTERMEDIATE UVEITIS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; INTERFERON-BETA; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS, INTERMEDIATE; VISUAL ACUITY;

EID: 27744461346     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.061119     Document Type: Article

References (25)

1. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 1997;49:1404-13.
2. Rucker CW. Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature. Mayo Clin Proc 1972;47:335-40.
3. Breger BC, Leopold IH. The incidence of uveitis in multiple sclerosis. Am J Ophthalmol 1966;62:540-5.
4. Porter R. Uveitis in association with multiple sclerosis. Br J Ophthalmol 1972;56:478-81.
5. Bamford CR, Ganley JP, Sibley WA, et al. Uveitis, perivenous sheathing and multiple sclerosis. Neurology 1978;28:119-24.
6. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993;100:818-24; discussion 825.
7. Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992;76:137-41.
8. James DG, Friedmann AI, Graham E. Uveitis. A series of 368 patients. Trans Ophthalmol Soc UK 1976;96:108-12.
9. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-5.
10. Biousse V, Trichet C, Bloch-Michel E, et al. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 1999;52:179-81.
11. Acar MA, Birch MK, Abbott R, et al. Chronic granulomatous anterior uveitis associated with multiple sclerosis. Graefes Arch Clin Exp Ophthalmol 1993;231:166-8.
12. Towler HM, Lightman S. Symptomatic intraocular inflammation in multiple sclerosis. Clin Experiment Ophthalmol 2000;28:97-102.
13. Wakefield D, Jennings A, McCluskey PJ. Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Experiment Ophthalmol 2000;28:103-6.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
15. BenEzra D, Ohno S, Secchi A, et al. Anterior segment intraocular inflammation guidelines. London: Martin Dunitz, 2000.
16. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
17. PRISMS. (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
18. Group CS. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001;132:463-71.
19. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
20. Constantinescu CS, Lavi E. Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr Eye Res 2000;20:71-6.
21. Adamus G, Amundson D, Vainiene M, et al. Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res 1996;44:513-8.
22. Okada AA, Keino H, Fukai T, et al. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:215-26.
23. Teitelbaum D, Meshorer A, Hirshfeld T, et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-8.
24. Munari LM, Lovati R, Boiko A. Therapy with qlatiramer acetate for multiple sclerosis (Cochrane Review). The Cochrane Library. 1 vol. Chichester: John Wiley, 2004.
25. Munari LM, Filippini G. Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol 2004;3:641.